223 related articles for article (PubMed ID: 21455998)
1. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome.
Khouri IF; Bassett R; Poindexter N; O'Brien S; Bueso-Ramos CE; Hsu Y; Ferrajoli A; Keating MJ; Champlin R; Fernandez-Vina M
Cancer; 2011 Oct; 117(20):4679-88. PubMed ID: 21455998
[TBL] [Abstract][Full Text] [Related]
2. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
3. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
Khouri IF; Lee MS; Saliba RM; Andersson B; Anderlini P; Couriel D; Hosing C; Giralt S; Korbling M; McMannis J; Keating MJ; Champlin RE
Exp Hematol; 2004 Jan; 32(1):28-35. PubMed ID: 14725898
[TBL] [Abstract][Full Text] [Related]
4. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia.
Richardson SE; Khan I; Rawstron A; Sudak J; Edwards N; Verfuerth S; Fielding AK; Goldstone A; Kottaridis P; Morris E; Benjamin R; Peggs KS; Thomson KJ; Vandenberghe E; Mackinnon S; Chakraverty R
Br J Haematol; 2013 Mar; 160(5):640-8. PubMed ID: 23293871
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, fludarabine, and total body irradiation as conditioning regimen before allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukemia: long-term prospective multicenter study.
Michallet M; Socié G; Mohty M; Sobh M; Bay JO; Morisset S; Labussière-Wallet H; Tabrizi R; Milpied N; Bordigoni P; El-Cheikh J; Blaise D
Exp Hematol; 2013 Feb; 41(2):127-33. PubMed ID: 23089183
[TBL] [Abstract][Full Text] [Related]
6. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Sorror ML; Storer BE; Sandmaier BM; Maris M; Shizuru J; Maziarz R; Agura E; Chauncey TR; Pulsipher MA; McSweeney PA; Wade JC; Bruno B; Langston A; Radich J; Niederwieser D; Blume KG; Storb R; Maloney DG
J Clin Oncol; 2008 Oct; 26(30):4912-20. PubMed ID: 18794548
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience.
Helbig G; Spałek A; Wieczorkiewicz-Kabut A; Markiewicz M; Kopera M; Zielińska P; Woźniczka K; Kopińska A; Grygoruk-Wiśniowska I; Koclęga A
Ann Hematol; 2019 Jun; 98(6):1477-1483. PubMed ID: 30919074
[TBL] [Abstract][Full Text] [Related]
8. Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.
Nishida T; Hudecek M; Kostic A; Bleakley M; Warren EH; Maloney D; Storb R; Riddell SR
Clin Cancer Res; 2009 Jul; 15(14):4759-68. PubMed ID: 19567591
[TBL] [Abstract][Full Text] [Related]
9. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
[TBL] [Abstract][Full Text] [Related]
10. Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation.
Farina L; Carniti C; Dodero A; Vendramin A; Raganato A; Spina F; Patriarca F; Narni F; Benedetti F; Olivieri A; Corradini P
Haematologica; 2009 May; 94(5):654-62. PubMed ID: 19377072
[TBL] [Abstract][Full Text] [Related]
11. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse.
Machaczka M; Johansson JE; Remberger M; Hallböök H; Lazarevic VLj; Wahlin BE; Omar H; Wahlin A; Juliusson G; Kimby E; Hägglund H
Med Oncol; 2013 Dec; 30(4):762. PubMed ID: 24214180
[TBL] [Abstract][Full Text] [Related]
12. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD.
Khouri IF; Wei W; Korbling M; Turturro F; Ahmed S; Alousi A; Anderlini P; Ciurea S; Jabbour E; Oran B; Popat UR; Rondon G; Bassett RL; Gulbis A
Blood; 2014 Oct; 124(14):2306-12. PubMed ID: 25145344
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
Brown JR; Kim HT; Armand P; Cutler C; Fisher DC; Ho V; Koreth J; Ritz J; Wu C; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Leukemia; 2013 Feb; 27(2):362-9. PubMed ID: 22955330
[TBL] [Abstract][Full Text] [Related]
15. Donor Killer Cell Immunoglobulin-Like Receptor Genotype Does Not Improve Graft-versus-Leukemia Responses in Chronic Lymphocytic Leukemia after Unrelated Donor Transplant: A Center for International Blood and Marrow Transplant Research Analysis.
Bachanova V; Weisdorf DJ; Wang T; Marsh SGE; Cereb N; Haagenson MD; Spellman SR; Lee SJ; Guethlein LA; Parham P; Miller JS; Cooley SA
Biol Blood Marrow Transplant; 2019 May; 25(5):949-954. PubMed ID: 30594542
[TBL] [Abstract][Full Text] [Related]
16. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
17. Reduced intensity conditioning regimens including alkylating chemotherapy do not alter survival outcomes after allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia compared to low-intensity non-myeloablative conditioning.
Andersen NS; Bornhäuser M; Gramatzki M; Dreger P; Vitek A; Karas M; Michallet M; Moreno C; van Gelder M; Henseler A; de Wreede LC; Schönland S; Kröger N; Schetelig J;
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2823-2834. PubMed ID: 31468122
[TBL] [Abstract][Full Text] [Related]
18. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Woyach JA; Ruppert AS; Heerema NA; Peterson BL; Gribben JG; Morrison VA; Rai KR; Larson RA; Byrd JC
J Clin Oncol; 2011 Apr; 29(10):1349-55. PubMed ID: 21321292
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
20. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
Gribben JG; Zahrieh D; Stephans K; Bartlett-Pandite L; Alyea EP; Fisher DC; Freedman AS; Mauch P; Schlossman R; Sequist LV; Soiffer RJ; Marshall B; Neuberg D; Ritz J; Nadler LM
Blood; 2005 Dec; 106(13):4389-96. PubMed ID: 16131571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]